Skip to main content

Home/ Dr. Goodyear/ Group items tagged pharmaceuticals

Rss Feed Group items tagged

Nathan Goodyear

High-Dose Vitamin C for Cancer Therapy - PMC - 0 views

  • diabetes [8], atherosclerosis [9], the common cold [10], cataracts [11], glaucoma [12], macular degeneration [13], stroke [14], heart disease [15], COVID-19 [16], and cancer.
  • 1–5% of the Vit-C inside the human cells
  • interaction between Fe(II) and H2O2 produces OH− through the Fenton reaction
  • ...35 more annotations...
  • metabolic activity, oxygen transport, and DNA synthesis
  • Iron is found in the human body in the form of haemoglobin in red blood cells and growing erythroid cells.
  • macrophages contain considerable quantities of iron
  • iron is taken up by the majority of cells in the form of a transferrin (Tf)-Fe(III) complex that binds to the cell surface receptor transferrin receptor 1 (TfR1)
  • excess iron is retained in the liver cells
  • the endosomal six transmembrane epithelial antigen of the prostate 3 (STEAP3) reduces Fe(III) (ferric ion) to Fe(II) (ferrous ion), which is subsequently transferred across the endosomal membrane by divalent metal transporter 1 (DMT1)
  • labile iron pool (LIP)
  • LIP is toxic to the cells owing to the production of massive amounts of ROS.
  • DHA is quickly converted to Vit-C within the cell, by interacting with reduced glutathione (GSH) [45,46,47]. NADPH then recycles the oxidized glutathione (glutathione disulfide (GSSG)) and converts it back into GSH
  • Fe(II) catalyzes the formation of OH• and OH− during the interaction between H2O2 and O2•− (Haber–Weiss reaction)
  • Ascorbate can efficiently reduce free iron, thus recycling the cellular Fe(II)/Fe(III) to produce more OH• from H2O2 than can be generated during the Fenton reaction, which ultimately leads to lipid, protein, and DNA oxidation
  • Vit-C-stimulated iron absorption
  • reduce cellular iron efflux
  • high-dose Vit-C may elevate cellular LIP concentrations
  • ascorbate enhanced cancer cell LIP specifically by generating H2O2
  • Vit-C produces H2O2 extracellularly, which in turn inhibits tumor cells immediately
  • tumor cells have a need for readily available Fe(II) to survive and proliferate.
  • Tf has been recognized to sequester most labile Fe(II) in vivo
  • Asc•− and H2O2 were generated in vivo upon i.v Vit-C administration of around 0.5 g/kg of body weight and that the generation was Vit-C-dose reliant
  • free irons, especially Fe(II), increase Vit-C autoxidation, leading to H2O2 production
  • iron metabolism is altered in malignancies
  • increase in the expression of various iron-intake pathways or the downregulation of iron exporter proteins and storage pathways
  • Fe(II) ion in breast cancer cells is almost double that in normal breast tissues
  • macrophages in the cancer microenvironment have been revealed to increase iron shedding
  • Advanced breast tumor patients had substantially greater Fe(II) levels in their blood than the control groups without the disease
  • increased the amount of LIP inside the cells through transferrin receptor (TfR)
  • Warburg effect, or metabolic reprogramming,
  • Warburg effect is aided by KRAS or BRAF mutations
  • Vit-C is supplied, it oxidizes to DHA, and then is readily transported by GLUT-1 in mutant cells of KRAS or BRAF competing with glucose [46]. DHA is quickly converted into ascorbate inside the cell by NADPH and GSH [46,107]. This decrease reduces the concentration of cytosolic antioxidants and raises the intracellular ROS amounts
  • increased ROS inactivates glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
  • ROS activates poly (ADP-ribose) polymerase (PARP), which depletes NAD+ (a critical co-factor of GAPDH); thus, further reducing the GAPDH associated with a multifaceted metabolic rewiring
  • Hindering GAPDH can result in an “energy crisis”, due to the decrease in ATP production
  • high-dose Vit-C recruited metabolites and increased the enzymatic activity in the pentose phosphate pathway (PPP), blocked the tri-carboxylic acid (TCA) cycle, and increased oxygen uptake, disrupting the intracellular metabolic balance and resulting in irreversible cell death, due to an energy crisis
  • mega-dose Vit-C influences energy metabolism by producing tremendous amounts of H2O2
  • Due to its great volatility at neutral pH [76], bolus therapy with mega-dose DHA has only transitory effects on tumor cells, both in vitro and in vivo.
pharmacybiz

David Webb - England New Chief Pharmaceutical Officer - 0 views

  •  
    David Webb has been appointed as the new chief pharmaceutical officer (CPO) for England. He will take over from Dr Keith Ridge who steps down next month after serving the role for sixteen year. Webb is currently chief pharmacist and clinical director for pharmacy and medicines optimisation at Guy's and Thomas's NHS Foundation Trust, London. Sharing the news of his appointment on Twitter on Friday afternoon (January 7), he said he was "really delighted and honoured" to be named the CPO for NHS England and that he was as the appointed Chief Pharmaceutical officer for "looking forward to working with pharmacy leaders, colleagues & teams across all sectors from February." He also extended his gratitude to the outgoing CPO for his "outstanding contribution" who, in turn, congratulated Webb and said it was "an honour to be handing over to him". In the same message, Dr Ridge thanked "all the great people I've worked with over the last 16 years for your support, friendship, good humour, great ideas & challenge. I wish you all well for the future."
Nathan Goodyear

JAMA Network | JAMA | Pharmaceutical Overdose Deaths, United States, 2010 - 1 views

  •  
    2010 pharmaceutical overdose #'s.  Over 38.000.
  •  
    i will be doing a lot of research on your articles. thank u. rita johnston
Nathan Goodyear

PLoS ONE: Obesity, the Endocannabinoid System, and Bias Arising from Pharmaceutical Spo... - 0 views

  •  
    good review of endocannabinoid system. More importantly, this article reveals the Bias present in the pharmaceutical arena, as it relates to their drug research.
pharmacybiz

Dr Nik Kotecha OBE - Distinguished Alumni Award Winner 2022 - 0 views

  •  
    Dr Nik Kotecha OBE, chairman of Morningside Pharmaceuticals and the Randal Charitable Foundation, has won the Distinguished Alumni Award at Imperial College London's Alumni Awards 2022. The annual awards honour outstanding alumni who have demonstrated sustained excellence in their personal and professional achievements and have made a substantial impact on society. Dr Kotecha, who founded Morningside in 1991, which manufactures and supplies generic and branded medicines to the UK and globally, said: "I'm thrilled to be honoured by the university in this way. "As a child growing up in Leicester my family had very little, but I was fortunate to be given opportunities to gain a good education. After finishing my degree in Newcastle; Professor Steve Ley FRS at Imperial College took a chance in accepting me into his eminent group and this really was the opportunity I needed to forge a career.
Nathan Goodyear

Association between industry affiliation and position on cardiovascular risk with rosig... - 1 views

  •  
    read to see how pharmaceutical monies control research and "expert opinion".  Expert opinion is open to the highest bidder.  Scientific research is become adulterated to say the least.
Nathan Goodyear

PLOS ONE: Increased Risk of Non-Fatal Myocardial Infarction Following Testosterone Ther... - 0 views

  • For all TT prescription subjects combined, the post/pre prescription rate ratio for MI (RR)was 1.36
  • In men aged 65 years and older the RR was 2.19 (1.27, 3.77), while in men under age 65 years the RR was 1.17
  • increasing RR with increasing age.
  • ...20 more annotations...
  • The RRs were 0.95 (0.54, 1.67) under 55 years
  • 1.35 (0.77, 2.38) at 55–59
  • 1.29 (0.71, 2.35) at 60–64,
  • 1.35 (0.44, 4.18) at 65–69, 1.62
  • 3.43 (1.54, 7.66) at 75 years and older
  • The adjusted post/pre RR for PDE5I across all ages was 1.08
  • For TT prescription, in men under age 65 years, the RR was 2.90 (1.49, 5.62) for those with a history of heart disease and 0.90 (0.61, 1.34) for those without
  • In men aged 65 year and older, the RR was 2.16 (0.92, 5.10) for those with a history of heart disease and 2.21 (1.09, 4.45) for those without.
  • Among men aged 65 years and older, we observed a two-fold increase in the risk of MI in the 90 days after filling an initial TT prescription
  • Among younger men with a history of heart disease, we observed a two to three-fold increased risk of MI in the 90 days following an initial TT prescription and no excess risk in younger men without such a history
  • Among older men, the two-fold increased risk was associated with TT prescription regardless of cardiovascular disease history
  • our own findings appear consistent with a higher frequency of thrombotic events following TT prescription among men with more extensive coronary vascular disease.
  • Our findings are consistent with a recent meta-analysis of placebo-controlled randomized trials of testosterone therapy lasting 12 or more weeks among mainly older men, which reported that testosterone therapy increased the risk of adverse cardiovascular-related events (OR = 1.54, 95%CI:1.09, 2.18), as well as serious adverse cardiovascular-related events (OR = 1.61, 95%CI:1.01, 2.56) which included myocardial infarction along with other conditions
  • This association appeared unrelated to average baseline testosterone level (p = 0.70) but varied by source of funding (p = 0.03), with a stronger summary effect in a meta-analysis of studies not funded by the pharmaceutical industry (OR = 2.06, 95%CI:1.34, 3.17) compared with studies funded by the pharmaceutical industry
    • Nathan Goodyear
       
      This supports prior analysis that studies done by pharmaceutical corps will be more favorable to their product(s) than those independently funded.  This is called bias.
  • the evidence supports an association between testosterone therapy and risk of serious, adverse cardiovascular-related events–including non-fatal myocardial infarction–in men
  • there is some evidence that low endogenous testosterone levels may also be positively associated with cardiovascular events
  • effects of endogenous and exogenous testosterone may differ. Exogenous testosterone (TT) is associated with physiologic changes that predispose to clotting and thrombotic disorders including increased blood pressure [18], polycythemia [19], reductions in HDL cholesterol [18], [20], and hyperviscosity of the blood and platelet aggregation. [20]–[23]; TT also increases circulating estrogens [24], [25] which may play a role in the observed excess of adverse cardiovascular-related events, given that estrogen therapy has been associated with this excess in both men and women
  • did not include information on the serologic or diagnostic indications for treatment.
  • no association between PDE5I prescriptions and the risk of MI
  • Recently TT has been increasing extraordinarily rapidly, including among younger men and among those without hormone measurement
  •  
    New cohort study finds increased risk of Testosterone in men > 65 and those : these are based in marketing-based medicine not evidence based medicine.
Nathan Goodyear

PLoS ONE: Antidepressants and Breast and Ovarian Cancer Risk: A Review of the Literatur... - 0 views

  •  
    Antidepressants shown to increase Breast and Ovarian Cancer risk in review of 61 articles. Clear relationship found, but exact risk still needs further research.  Interestingly, the pharmaceutical industry's research, showed no risk.
Nathan Goodyear

Heavy Metal-induced Immunotoxicity and Its Mechanisms | ResearchGate - 0 views

  • Heavy Metal-induced Immunotoxicity and Its Mechanisms
  •  
    Heavy Metal-induced Immunotoxicity and Its Mechanisms
Nathan Goodyear

Progesterone receptor could slow breast cancer growth | News | Pharmaceutical Journal - 0 views

  •  
    summary of previously posted link on progesterone and its inhibition of ER alpha signaling.
vishal Parasrampuria

28mm PCO Pet Preforms - 0 views

  •  
    Established in 1977, we are counted amongst trusted manufacturers and suppliers of superior grade PCO Neck PET Preforms. The offered preform is widely utilized in pharmaceutical, cosmetic, soft beverage and food industries in various application. Superlative quality PET and cutting-edge technology, this products is checked thoroughly in order to ensure flawlessness. Aside from this, our produced 28mm PCO Preforms
Rahul Sharma

Cellulose Nitrate - CN Gridded Membrane Filters - 0 views

  •  
    Buy best quality CN Gridded Membrane Filters at Axiva. This membrane filters are ideal for analytical method requiring qualitative, enrichment method microorganism counts for the detection of microbial contamination in food beverages, pharmaceuticals and cosmetics.
ashleyobama

Nembutal Liquid | pills nembutal |Nembutal Liquid | - 0 views

  •  
    Nembutal Liquid is best quality and prices at First Trust Chemicals. Visit our website and place your order online. Nembutal Liquid Pentobarbital (trade name: Nembutal) is a drug from the barbiturate class. It was widely used during the 1940s and 1950s as a sleeping pill (i.e. hypnotic) or anti-anxiety drug (i.e. sedative). Unlike modern sleeping pills, Nembutal is highly lethal in overdose. Because it is very reliable and brings about peaceful death, it is one of drugs of choice for assisted suicide. Nembutal is used by euthanasia organizations in the United States (Oregon Death With Dignity Act), Switzerland (Dignitas) and The Netherlands. Nembutal Liquid Since it was so easy to overdose on Nembutal (whether accidentally or intentionally), it was almost universally taken off the market and replaced by safer sleeping pills. Nembutal was removed from the Australian prescribing schedule in 1998. However, Nembutal remains in use by veterinary surgeons in order to euthanase bigger animals. Many people were successful in obtaining veterinary Nembutal for their suicide. The famous American actress Marilyn Monroe supposedly used Nembutal to end her life. The brand name "Nembutal" was coined by Dr. John S. Lundy, who started using it in 1930, from the structural formula of the sodium salt-Na (sodium) + ethyl + methyl + butyl + al (common suffix for barbiturates). Nembutal is trademarked and manufactured by the Danish pharmaceutical company Lundbeck
pharmacybiz

PDA expresses concerns as Boots decides to cut opening hours at some pharmacies - Lates... - 0 views

  •  
    The Pharmacists' Defence Association (PDA) has expressed concerns over Boots UK's decision to reduce supplemental opening hours at some pharmacies. The association stated: "Some pharmacists and other staff at Boots are being notified this week of changes to opening hours at their place of work, with local briefings taking place. The PDA are supporting their members to deal with any potential impact on their employment." It said that reducing pharmacy opening hours would affect patients' access to a trusted healthcare professional, especially if it is being done by the largest community pharmacy multiple. It even called upon the NHS to adequately fund community pharmacies to ensure they remain open when patients and local communities need their services. Meanwhile, Boots management has informed PDA that most of its employees are not pharmacists, and "less pharmacists are expected to be directly impacted by these changes than other colleagues," PDA said.
pharmacybiz

9,000 Pharmacy Contractors Benefited From Advance Payment - 0 views

  •  
    Nearly 9,000 pharmacy contractors benefitted from earlier advance payment in January, Pharmaceutical Services Negotiating Committee (PSNC) said in an update. Contractors who declared their December FP34C submission figures (for the dispensed prescriptions) through the Manage Your Service (MYS) portal by January 6, would have received earlier advance payments on January 12. Meanwhile, all contractors who made submissions after January 6 or used the FP34C paper document, will receive payments as per the normal payment schedule i.e. on February 1, 2022. PSNC encouraged contractors to submit their monthly declaration through the MYS portal by the 5th of the month to avail early payments.
pharmacybiz

Community Pharmacies 22 Million Covid-19 Jabs In One Year - 0 views

  •  
    Community pharmacies played a central role in the government's response to the Covid-19 pandemic, delivering more than 22 million jabs in the past 12 months. Besides delivering millions of jabs, latest figures from NHS England and NHS Improvement (NHSE&I) revealed a 50 per cent increase in the number of pharmacies delivering Covid boosters compared from October 2021 to January 2022. NHSE&I released the data on Friday (January 14) to thank community pharmacy teams for their work during the crisis time. Lauding the efforts made by community pharmacy teams during the pandemic, Pharmaceutical Services Negotiating Committee (PSNC) director of NHS Services Alastair Buxton said: "Just over a year ago we were fighting for Government recognition of the part community pharmacy could play in administering Covid vaccines, so a year later it is great to see the efforts of the pharmacy vaccination sites being praised by NHSE&I, with recognition of the significant role they have played in the overall programme.
pharmacybiz

DHSC adds Dexcom One transmitter to March 2023 Drug Tariff - 0 views

  •  
    Department of Health of Social Care (DHSC) has confirmed that the Dexcom One Transmitter will be added to Part IXA of the March 2023 Drug Tariff. "Previously, patients were advised to obtain the free-of-charge Dexcom One transmitters directly from the pharmacies, without a prescription, as the original Drug Tariff application for the transmitter was unsuccessful," said the Pharmaceutical Services Negotiating Committee (PSNC) It has raised concerns with DHSC and Dexcom that these distribution arrangements for transmitters are unacceptable because they result in extra unfunded activity for community pharmacies. Both, DHSC and Dexcom acted upon these concerns by agreeing to add the Dexcom One transmitter to the Drug Tariff from March 2023. At the same time, Dexcom One CGM System (containing 1 sensor, 1 sensor applicator, 1 transmitter) will also be added to the March Drug Tariff.
Nathan Goodyear

Anabolic and androgenic activities of Bulbine natalensis stem in male Wistar rats: Phar... - 0 views

  •  
    Bulbine natalensis Baker stem found to increase Testosterone by up to 350% in animal studies in 2 weeks.  The dose with the optimum response was 25 and 50 mg/kg, with the most best effect at 50 mg/kg.  LH and FSH production was increase but exact mechanism not discussed.  Only abstract available here.
1 - 20 of 39 Next ›
Showing 20 items per page